Rein Therapeutics, Inc. (RNTX) Net income 2016–2025
Rein Therapeutics, Inc. (RNTX) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$49.9MFY2025 · since FY2016: -$18.1M → -$49.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$49.9M | +20.7% |
| FY2024 | -$62.9M | -299.7% |
| FY2023 | -$15.7M | +42.4% |
| FY2022 | -$27.3M | -4.5% |
| FY2021 | -$26.2M | +4.3% |
| FY2020 | -$27.3M | +6.9% |
| FY2019 | -$29.4M | +6.9% |
| FY2018 | -$31.5M | -39.6% |
| FY2017 | -$22.6M | -24.7% |
| FY2016 | -$18.1M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More RNTX financial trends
RNTX RevenueRNTX Net marginRNTX Gross profitRNTX Gross marginRNTX Operating incomeRNTX Operating marginRNTX Operating cash flowRNTX Free cash flowRNTX Capital expendituresRNTX Return on equityRNTX Stock buybacksRNTX Dividends paidRNTX Total assetsRNTX Total liabilitiesRNTX Shareholders’ equityRNTX overview →